Loading
Life sciences · Journal article
Life Metabolism · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Gut enteroendocrine cells (EECs) sense luminal cues and secrete more than 20 hormones that orchestrate physiological responses across multiple organ systems. Beyond their established roles in gastrointestinal (GI) regulation, EECs and their hormones are integral regulators of systemic metabolism. Dysregulated metabolic states can profoundly alter EEC subpopulation and secretion profile, and these changes further contribute to pathologies in various tissues including the liver, pancreas, adipose tissue, and the cardiovascular system. Importantly, gut hormone-based therapies, such as glucagon-like peptide‑1 (GLP-1) receptor agonists, have achieved remarkable success in obesity and diabetes treatment, and emerging evidence supports their potential applications in nonalcoholic steatohepatitis, atherosclerosis, and other metabolic diseases. In this review, we highlight the expanding roles of EECs in extraintestinal metabolic regulation, examine how diet and disease reshape EEC function, and discuss the translational opportunities of targeting gut hormone pathways for the treatment of metabolic disorders.